Department of Urology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
Can J Urol. 2020 Jun;27(3):10250-10256.
To evaluate the impact of an 'opt-in' non-narcotic postoperative pain regimen on narcotic utilization and patient-reported pain scores.
A prospective, non-blinded pre- and post-interventional trial was conducted, including a lead-in period for baseline evaluation. The intervention group received a new pain protocol prioritizing non-narcotic medications, an 'opt-in' requirement for opiates, and standardized patient education. Study outcomes included opiate prescription and utilization (measured in Morphine Equivalent Doses) and reported pain scores on postoperative day (POD) 1, discharge and follow up.
At discharge, 70% fewer patients were prescribed any opioids (ARR: -0.7; p < 0.001); the amount prescribed was reduced by 95% (pre-intervention 69.3 mg versus post-intervention 3.5 mg, p < 0.001). Mean opioids used following discharge decreased by 76% (14.7 mg versus 3.5 mg, p = 0.011). In a subgroup analysis of robotic prostatectomies, there was a 95% reduction in mean opioids prescribed at discharge (64.6 mg versus 3.2 mg, p < 0.001) and 82% reduction in utilization over entire postoperative course (87.6 mg versus 15.7 mg, p = 0.001). There was no significant difference in pain scores between intervention groups at POD 1, discharge and follow up for patients (entire cohort and post-prostatectomy).
A standardized pain protocol with 'opt-in' requirements for opiate prescription, emphasis on non-narcotic medications, and patient education, resulted in significant reductions in opioid use. Simple frameshifts in pain management can yield significant gains in the opioid epidemic.
评估“选择加入”非阿片类术后疼痛方案对阿片类药物利用和患者报告疼痛评分的影响。
进行了一项前瞻性、非盲的干预前后试验,包括基线评估的导入期。干预组接受了新的疼痛方案,优先使用非阿片类药物,阿片类药物采用“选择加入”的要求,并进行标准化的患者教育。研究结果包括术后第 1 天(POD)、出院和随访时的阿片类药物处方和利用(以吗啡等效剂量衡量)以及报告的疼痛评分。
出院时,开具任何阿片类药物的患者减少了 70%(ARR:-0.7;p < 0.001);开具的药物减少了 95%(干预前 69.3 毫克,干预后 3.5 毫克,p < 0.001)。出院后使用的阿片类药物平均减少了 76%(14.7 毫克对 3.5 毫克,p = 0.011)。在机器人前列腺切除术的亚组分析中,出院时开具的平均阿片类药物减少了 95%(64.6 毫克对 3.2 毫克,p < 0.001),整个术后过程中使用量减少了 82%(87.6 毫克对 15.7 毫克,p = 0.001)。对于所有患者(整个队列和前列腺切除术后),干预组在 POD 1、出院和随访时的疼痛评分没有显著差异。
采用“选择加入”阿片类药物处方要求、强调非阿片类药物和患者教育的标准化疼痛方案,显著减少了阿片类药物的使用。在疼痛管理方面进行简单的调整,就可以在阿片类药物流行中取得显著成效。